FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to the production of antagomirs to miRNA, and can be used in medicine for the treatment of vascular disease selected from the group consisting of peripheral vascular occlusive disease, coronary heart disease, cerebrovascular disease, vasculitis, atherosclerosis, vascular remodeling in response to injury or restenosis. Pharmaceutical composition with antagomir molecule miRNA-100 is prepared for the positive modulation of the growth of blood vessels, in this regard, for use in modulating the proliferation, tube formation and sprouting activities on endothelial cells or modulation of adhesion molecule expression by these cells.
EFFECT: invention improves the effectiveness of angiogenic therapy.
7 cl, 17 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR | 2014 |
|
RU2668794C2 |
| RECOMBINANT PLASMID DNA CODING microRNA hsa-miR-145-3p, AND ITS USE AS POSITIVE CONTROL IN REAL-TIME PCR FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT | 2025 |
|
RU2837873C1 |
| RECOMBINANT PLASMID DNA CODING microRNA hsa-miR-143-5p, AND ITS USE AS POSITIVE CONTROL IN REAL-TIME PCR FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT | 2025 |
|
RU2837872C1 |
| MIR-155 INHIBITORS FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) | 2016 |
|
RU2718534C2 |
| RECOMBINANT PLASMID DNA CODING microRNA hsa-miR-143-3p, AND ITS USE AS POSITIVE CONTROL IN REAL-TIME PCR FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT | 2025 |
|
RU2837882C1 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| COMPOSITIONS AND METHODS FOR TREATING HAEMOGLOBINOPATHIES | 2015 |
|
RU2707540C2 |
| METHOD FOR INHIBITING TUMOUR METASTASIS BY SUPPRESSING DEDIFFERENTIATION OF TUMOUR CELLS | 2023 |
|
RU2840966C1 |
